National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Alemtuzumab (Lemtrada®) is indicated for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features

 Rapid Review

Commenced Completed Outcome
08/11/2013 02/12/2013 Full HTA Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
 28/01/2014  25/06/2014 Reimbursement Recommended

 The NCPE recommends reimbursement of alemtuzumab (Lemtrada®).

NCPE Summary